These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32611582)

  • 1. The Association of
    Wang X; Yu X; Krauthammer M; Hugo W; Duan C; Kanetsky PA; Teer JK; Thompson ZJ; Kalos D; Tsai KY; Smalley KSM; Sondak VK; Chen YA; Conejo-Garcia JR
    Cancer Epidemiol Biomarkers Prev; 2020 Sep; 29(9):1792-1799. PubMed ID: 32611582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
    Li X; Pasche B; Zhang W; Chen K
    JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender and melanoma subtype-based prognostic implications of MUC16 and TTN co-occurrent mutations in melanoma: A retrospective multi-study analysis.
    Kodali N; Alomary S; Bhattaru A; Eldaboush A; Schwartz RA; Lipner SR
    Cancer Med; 2024 Sep; 13(17):e70199. PubMed ID: 39240165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring
    Wang Q; Yang Y; Yang M; Li X; Chen K
    Aging (Albany NY); 2020 Jun; 12(11):10827-10843. PubMed ID: 32491995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of
    Wang Z; Hou H; Zhang H; Duan X; Li L; Meng L
    Am J Transl Res; 2022; 14(2):849-862. PubMed ID: 35273689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation of MUC16 Is Associated With Tumor Mutational Burden and Lymph Node Metastasis in Patients With Gastric Cancer.
    Zhang F; Li X; Chen H; Guo J; Xiong Z; Yin S; Jin L; Chen X; Luo D; Tang H; Mao C; Lian L
    Front Med (Lausanne); 2022; 9():836892. PubMed ID: 35211490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC16 mutation is associated with tumor grade, clinical features, and prognosis in glioma patients.
    Ferrer VP
    Cancer Genet; 2023 Jan; 270-271():22-30. PubMed ID: 36436416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
    Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
    PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
    Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
    Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients.
    Aoude LG; Bonazzi VF; Brosda S; Patel K; Koufariotis LT; Oey H; Nones K; Wood S; Pearson JV; Lonie JM; Arneil M; Atkinson V; Smithers BM; Waddell N; Barbour AP
    Sci Rep; 2020 Oct; 10(1):17687. PubMed ID: 33077847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden.
    Lin J; Lin Y; Huang Z; Li X
    Comput Math Methods Med; 2020; 2020():8836493. PubMed ID: 33273963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive characterization of MUC16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.
    Liu T; Wu L; Liu J; Chen H; Zhu B; Qiao D; Zhu Y; Liu T; Chen Q; Hu A
    Medicine (Baltimore); 2023 Nov; 102(44):e35481. PubMed ID: 37932988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between
    Hu S; Zhao X; Qian F; Jin C; Hou K
    Comput Math Methods Med; 2021; 2021():1522250. PubMed ID: 34603481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma.
    Kang K; Xie F; Mao J; Bai Y; Wang X
    Front Oncol; 2020; 10():573141. PubMed ID: 33072607
    [No Abstract]   [Full Text] [Related]  

  • 16. Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas.
    Jonckheere N; Van Seuningen I
    J Transl Med; 2018 Sep; 16(1):259. PubMed ID: 30236127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-omics analysis of tumor mutation burden combined with immune infiltrates in melanoma.
    Jiang F; Wu C; Wang M; Wei K; Zhou G; Wang J
    Clin Chim Acta; 2020 Dec; 511():306-318. PubMed ID: 33164879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
    Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
    Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing a prognostic model for skin melanoma based on the persistent tumor mutation burden and determining IL17REL as a therapeutic target.
    Xu M; Ma X; Wang Y; Yu Z; Zheng X; Dai H; Xue C
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):313. PubMed ID: 38900244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma.
    You Z; Lv M; He X; Pan Y; Ge J; Hu X; Zheng Y; Huang M; Zhou C; You C
    Front Immunol; 2022; 13():871756. PubMed ID: 35990677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.